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THE EFFECT OF A PRIOR AUTHORIZATION PROGRAM
FOR PROTON-PUMP INHIBITORS ON MEDICATION
PERSISTENCE AMONG THE ELDERLY
Devine JW1, Trice S1, Allerman AA1, Bacon TA2
1Department of Defense Pharmacoeconomic Center, Fort Sam Houston, TX, USA, 
2TRICARE Management Activity, Falls Church, VA, USA
OBJECTIVES: To evaluate the effect of a prior authorization (PA) requirement on 
medication persistence in the elderly following implementation of a step therapy 
program for proton-pump inhibitors (PPI) in the Military Health System. METHODS:
Our study population comprised 33,226 TRICARE beneﬁ ciaries q 65 years old with
a PPI prescription between October 24, 2007 and January 31, 2008. The PA required
patients without a PPI prescription in the last 180 days to receive a trial of the pre-
ferred product (omeprazole or esomeprazole) before receiving another PPI. The study 
cohort (n  15,294) included patients affected by the PA requirement; the reference 
cohort (n  17,932) was not affected because patients received an initial ﬁ ll for the 
preferred product. Medication persistence was measured as 1) proportion of days 
covered (PDC) with persistence deﬁ ned as q 80% of days covered, and (2) time to 
ﬁ rst gap  30 days following initiation. Differences in medication persistence between 
cohorts were detected using logistic regression and a proportional hazards model,
adjusted for age, gender, and type of pharmacy (community vs. mail order). RESULTS:
In the 6 months following initiation of PPI treatment, 46% of study subjects were not
persistent (PDC  80%), while 77% experienced a gap in treatment  30 days. Expo-
sure to the PA requirement decreased the odds of being persistent with treatment at 
6 months by 39% (OR 0.61; 95% CI 0.58¨C0.64) and increased the risk of experienc-
ing a 30-day gap in treatment by 17% (HR 1.17; 95% CI 1.14¨C1.20). CONCLU-
SIONS: The prior authorization program was associated with lower rates of medication
persistence. Further study should evaluate whether the reduction in persistence had 
an effect on patient clinical outcomes.
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RESPONSIVENESS TO CHANGE AND CLINICALLY RELEVANT 
IMPROVEMENTS OF THE SF-36 QUESTIONNAIRE IN SWEDISH
PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE
Wahlqvist P, Medin J, Rydén A
AstraZeneca R&D Mölndal, Mölndal, Sweden
OBJECTIVES: To assess responsiveness to change of the Short Form-36 (SF-36)
questionnaire in patients with gastroesophageal reﬂ ux disease (GERD), and whether 
clinically relevant improvements in symptoms correlate with improvements in the 
SF-36. METHODS: The SF-36 (acute version, 1-week recall, score: 0–100) was used
in a methodological study in 205 Swedish GERD patients before and after 4 weeks’ 
proton pump inhibitor (PPI) treatment. After treatment, patients completed a 7-graded 
Overall Treatment Evaluation (OTE) questionnaire with regard to GERD symptoms,
from which three main OTE response groups were identiﬁ ed (no or small improve-
ment, moderate improvement, large improvement). Responsiveness was assessed by 
calculating effect sizes (ES) for all patients and by OTE response group. Clinically
relevant improvements were assessed by comparing SF-36 changes to Swedish popula-
tion norm values and by investigating SF-36 changes by OTE response group. 
RESULTS: The mean overall before-after PPI treatment change for the Physical Com-
ponent (PC) and Mental Component (MC) scores of the SF-36 were 4.6 and 4.4, 
respectively, and ranged from 5.1 to 18.9 for the eight individual SF-36 dimensions 
(all p  0.001). However, SF-36 scores after treatment were similar to Swedish popula-
tion norm values only in those who reported a large improvement in treatment effect 
on symptoms, according to the OTE. Mean OTE changes and ES consistently increased
with degree of improvement for all eight SF-36 dimensions and the PC and MC scores,
demonstrating an association between clinically relevant improvements in symptoms 
and improvements in SF-36. Overall, ES were moderate to high in patients experienc-
ing a large improvement according to the OTE. CONCLUSIONS: Successful GERD 
treatment, as reported by patients, resulted in both statistically signiﬁ cant and clini-
cally relevant improvements in SF-36 scores. The SF-36 was found to be responsive
to change. Given the methodology used, results should be regarded as applicable only 
in a GERD population.
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RESPONSIVENESS TO CHANGE AND CONSTRUCT VALIDITY
OF THE WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT
QUESTIONNAIRE FOR GASTROESOPHAGEAL REFLUX DISEASE
(WPAI : GERD) IN SWEDISH PATIENTS
Wahlqvist P1, Medin J1, Karlsson M1, Reilly MC2
1AstraZeneca R&D Mölndal, Mölndal, Sweden, 2Margaret Reilly Associates, Inc, New York, NY, 
USA
OBJECTIVES: To assess responsiveness to change and construct validity of the Work 
Productivity and Activity Impairment questionnaire for gastroesophageal reﬂ ux
disease (WPAI : GERD), a GERD-speciﬁ c adaptation of the Speciﬁ c Health Problem 
version of the WPAI. METHODS: The WPAI : GERD measures GERD-speciﬁ c work
absenteeism, presenteeism (reduced productivity while at work) and impairment in 
regular daily activities other than work during the preceding week. It was completed
by 205 employed Swedish patients before and after 4 weeks’ proton pump inhibitor 
treatment for GERD. Responsiveness was assessed by calculating effect sizes (ES) for
all patients and by response group according to a 7-graded Overall Treatment Evalu-
ation (OTE) questionnaire. Construct validity was assessed by investigating the rela-
tionship between WPAI measures and symptoms, as well as health-related quality of 
life (HRQL). RESULTS: Absenteeism was not included in the analyses due to very 
high variability in the results and the relatively low mean before-after treatment change 
(0.4 hours; 95% CI: 2.4, 3.1). The mean overall before-after treatment change in 
percent reduced productivity was 15.3% for presenteeism (from 25.5% to 10.2%; 
p  0.001) and 18.3% for impairment in daily activities (from 31.5% to 13.2%;
p  0.001). ES were moderate for the whole study population (presenteeism: 0.67, 
activity impairment: 0.79) and were large in patients experiencing a large improvement 
according to the OTE (presenteeism: 0.98, activity impairment: 1.22). Cross-sectional 
Pearson correlation coefﬁ cients between WPAI variables and symptoms (range: 0.06–
0.67), as well as HRQL (range: 0.19–0.79) supported cross-sectional construct validity
of the WPAI : GERD. Corresponding change score correlations (range for symptoms:
0.17–0.56, range for HRQL: 0.15–0.61) and a descriptive analysis of change in pro-
ductivity by change in heartburn severity also supported longitudinal construct valid-
ity. CONCLUSIONS: Results indicated that the WPAI : GERD measures of presenteeism 
and activity impairment are responsive to change. Cross-sectional, as well as longitu-
dinal, construct validity of the measures was conﬁ rmed.
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ADULT CANADIANS SUFFERING FROM ACID RELATED
DISEASES: PATIENT REPORTED ATTITUDES, PERCEPTIONS, 
AND IMPACT ON THEIR LIFE
Beamer B, Ciobanu A, Liovas A
AstraZeneca, Mississauga, ON, Canada
OBJECTIVES: To understand patient attitudes and perceptions towards acid related 
diseases (ARD). Furthermore to reveal the degree to which ARD affect patient lives,
and uncover their level of satisfaction with prescription medicines. METHODS: On 
line Canadians 18 years were solicited by email by a national interactive research 
organization. Those who reported a diagnosis of stomach ulcer, duodenal ulcer,
heartburn, acid reﬂ ux/GERD/reﬂ ux esophagitis, Irritable Bowel Syndrome (IBS) or 
dyspepsia/stomach pain, and who have taken prescription medicines for at least one 
month were directed to an on line interactive English or French survey instrument 
from July–August 2007. RESULTS: A total of 1033 ARD patients responded(East 
106,Quebec 260,Ontario 364,West 303). The following conditions were reported: 
stomach ulcer (64); duodenal ulcer (20); heartburn (219); Acid Reﬂ ux/GERD (647); 
Dyspepsia (80); IBS (7). A 2-year average delay was reported before talking with their
physicians about their symptoms. They experience numerous troublesome symptoms
prior to taking medication including heartburn, acidic taste, stomach pain, indigestion,
chest pain, and sleeping problems. Prior to seeking care and medication for these 
symptoms, four in ten reported they felt tired, worn out and were unable to sleep.
Nearly one in ten report missing work. Patients make changes to their diet, social,
work and daily activities to compensate for their conditions. 80% experienced at least 
one somewhat severe or severe symptom prior to treatment, while only 21% did post
treatment. 45% of patients were referred to a specialist with an average wait time
over 12 weeks. Of those referred, 47% underwent an endoscopy. CONCLUSIONS:
Canadians suffering from ARD experience numerous troublesome symptoms that 
negatively impact their quality of life, including missing work, yet on average they
wait two years before seeking help from their physician. Nearly one half are referred 
to specialists and about half of these receive an endoscopy.
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FACTORS INFLUENCING GASTROESOPHAGEAL REFLUX
DISEASE OUTPATIENTS’ CHOICES TO ACCESS DIFFERENT TIERS
OF MEDICAL FACILITIES: THE PRELIMINARY STUDY OF A
DISCRETE CHOICE EXPERIMENT
Tseng JH1, Chen LC1, Kuo C2, Lu C1
1Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 2Kaohsiung Municipal Hsiao-Kang 
Hospital, Kaohsiung, Taiwan
OBJECTIVES: Taiwan’s single payer national health insurance system provides gener-
ous coverage and patients’ full freedom to access different tiers of medical facilities. 
Government’s attempt to divert outpatient care utilisation into primary care by largely 
increasing co-payment only showed limited effects. To determine the relative impor-
tance of factors (attributes) associated with patients’ choices of accessing different tiers
of medical facilities, we conducted a qualitative study on outpatients with gastro-
esophageal reﬂ ux disease (GERD), who generally do not need aggressive treatment. 
METHODS: Focus groups were conducted on outpatients with GERD from different 
tiers of medical facilities in Southern Taiwan. RESULTS: Seven focus groups were held
in medical centers (2), regional hospitals (2), physician clinics (2), and local community
(1), recruiting 35 participants from cities and an off-shore island. Reputation of 
doctors and scale of medical facilities are the highest priorities and unanimous con-
siderations of all participants. Distance (transportation convenience) is also an impor-
tant attribute for accessing medical care. Information sources for making decision
includes consultation with relatives and friends, searching internet information, or 
rank of hospitals and doctors from media. Participants generally thought the current
out-of-pocket payment (OPP) is expensive, especially when accessing medical centers,
but they still preferred and felt worthy to visit higher tiers of medical facilities due to 
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their trust on quality (better medical cares, drugs and equipments), and also doctors
may use cost-saving strategies such as continuous prescriptions to help them. CON-
CLUSIONS: The attributes for GERD outpatients’ choices of accessing medical facili-
ties have been identiﬁ ed. Participants with different socioeconomic backgrounds in 
Southern Taiwan are aware of the increasing OPP, but the current OPP does not seem 
to impact on the affordability and accessibility of treatment. Future study is going to 
determine the relative importance of attributes and how different OPP can inﬂ uence
on decision making.
PGI17
EXAMINATION OF PROTON PUMP INHIBITOR (PPI) 
UTILIZATION AMONG GASTROESOPHAGEAL REFLUX (GERD) 
PATIENTS USING ELECTRONIC MEDICAL RECORDS (EMR)
Mody R1, Meissner BL2, Shaheen N3
1Takeda Pharmaceuticals North America, Inc, Deerﬁ eld, IL, USA, 2Xcenda, Palm Harbor, FL, 
USA, 3University of North Carolina, Chapel Hill, NC, USA
OBJECTIVES: To examine PPI utilization among patients with non-erosive GERD
(NERD), erosive esophagitis (EE) and Barrett’s esophagus (BE). METHODS: We
conducted an observational cohort study using EMRs obtained from a fully integrated 
health delivery system located in the mid-Atlantic region of the US. Incident cases of 
BE, EE, and NERD were identiﬁ ed between July 1, 2004–January 25, 2007. Patients 
were required to have encounter data for 6 months before and 12 months following 
their index diagnosis. Frequency of PPI use, time to PPI initiation, dosing frequency,
and switching patterns among the three cohorts at 52 weeks post diagnosis were
compared using NERD as the reference group. RESULTS: 12,273 patients met the 
inclusion criteria and included 79.6% NERD, 17.9% EE and 2.3% BE patients. A 
higher proportion of NERD and EE patients received a PPI as their initial pharmaco-
logic therapy (90.5% and 92.2%; p  0.0140) compared to 70.5% (p  0.0001) of 
BE patients. Greater than 90% of NERD and EE (p  0.0001) patients started initial
PPI therapy within 8 weeks post diagnosis compared to 71.6% (p  0.0001) of BE
patients. Majority of patients were prescribed once daily PPI therapy [NERD 79.4%;
BE 68.2% (p  0.0001); EE 73.6% (p  0.0001)] with a substantial proportion of 
patients on twice daily therapy [NERD 12.3%; BE 31.3% (p  0.0001); EE 15.2% 
(p  0.0003)]. Switching among initial PPI therapy occurred more often within BE 
patients (14.4%; p  0.0083) as compared to NERD and EE patients (9.0%, 9.3%; 
p  0.6896). There were no signiﬁ cant differences in patients reducing their PPI fre-
quency from twice daily to once daily therapy (NERD 24.5%, BE 18.5%, EE 25.7%).
CONCLUSIONS: A substantial proportion of patients with GERD are on twice daily 
PPI regimen. Switching between various PPI agents is common among GERD patients.
Future research should focus on the clinical and economic implications of twice daily 
PPI use and switching among PPIs.
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EXAMINING PROTON PUMP INHIBITOR (PPI) TREATMENT 
PATTERNS AMONG PATIENTS WITH SELECTED UPPER 
GASTROINTESTINAL CONDITIONS
De Leon MC1, Mody R1, Boulanger L2
1Takeda Pharmaceuticals, Deerﬁ eld, IL, USA, 2Abt Bio-Pharma Solutions, Inc., Lexington, MA, 
USA
OBJECTIVES: To retrospectively examine patterns of PPI treatment in commercially
insured adults (q18 years of age) with selected upper gastrointestinal conditions.
METHODS: Patients were selected if they were newly dispensed a PPI in 2003 or
2004 (ﬁ rst PPI claim is “index date”) and were continuously enrolled in the 12 months
pre- and post-index. Based on ICD-9 CM diagnosis codes, four disease cohorts were
constructed: GERD, GERD-like symptoms (787.1), Erosive Esophagitis (EE), and
Barrett’s Esophagus (BE). Post-index length of treatment (LOT) was estimated as the 
cumulative days of index PPI therapy dispensed. Patients were considered “adherent” 
if the medication possession ratio (LOT/365 days) was q80%. Discontinuation of PPI 
medication was deﬁ ned as 90 days without available treatment. PPI adherence, dis-
continuation and LOT were compared between the four subgroups. RESULTS: The 
study population included 138,598 patients (91.7% GERD; 1.6% GERD-like symp-
toms; 4.1% EE; 2.7% BE). Mean (SD) number of reﬁ lls of index PPI for patients with
GERD-like symptoms, GERD, EE and BE were 2.9 (3.3), 3.2 (3.4), 4.1 (3.6) and 4.2 
(3.6), respectively (p  0.01). LOT was signiﬁ cantly (p  0.01) longer for BE [197.4
days (120.9)], EE [194.9 (121.4)], and GERD patients [154.3 (116.6)] compared to 
patients with GERD-like symptoms [142.9 (115.8)]. There were signiﬁ cant differences 
(p  0.01) in adherence to index PPI between BE patients (33.2%), EE patients 
(32.7%), GERD patients (20.7%), and patients with GERD-like symptoms (18.8%).
During the study period, a higher proportion of patients with GERD-like symptoms
(63.6%, p  0.01), GERD (58.2%, p  0.01) and EE (40.3%, p  0.04) discontinued
PPI treatment compared with BE patients (37.9%). CONCLUSIONS: Patients with 
BE and EE, generally considered as a more severe form of GERD, showed higher 
adherence with and lower discontinuation of PPI treatment compared to patients with 
GERD and GERD-like symptoms. Additional studies of the clinical and economic
implications of discontinuing PPI treatment should be conducted.
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REDUCING MEDICAL COSTS THROUGH PREVENTING
LABORATORY ERRORS: AN EVALUATION OF BAYESIAN NETWORK 
MODEL IN DETECTING ERRORS OF LIVER ENZYME LAB VALUES
Le QA, Doctor JN
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: Medical errors are a major problem in the United States. The Institute
of Medicine estimates that medical errors cost the U.S. approximately $37.6 billion, 
of which $17 billion are preventable. Our objectives are to develop a Bayesian network 
(BN) model to detect value errors in blood lab and to compare performance of our 
model with an existing automated ruled-based approach (LabRespond), and a logistic 
regression model. METHODS: The sample consisted of 5800 observations from the 
National Health and Nutrition Examination Survey dataset. The performance was 
assessed by the area under the receiver-operating characteristics curves (AUCs) using 
a 10-fold cross validation methodology. Small, medium, and large errors were ran-
domly generated and added to liver enzymes (AST, ALT, and LDH). The outcome of 
interest was the correct detection of liver enzymes as “error” or “normal.” In BN, the
outcome was predicted by exploiting probabilistic relationships among AST, ALT, 
LDH, and gender. Addition to AST, ALT, LDH, and gender, LabRespond required 
more analyte information (GGT, ALP, and total bilirubin) to achieve optimal predic-
tion. For the Logistic model, the model was determined by stepwise selection among 
analytes that were signiﬁ cant at A  0.05. RESULTS: The BN was predictive of added 
errors with small [AUC  0.644 (0.023)], medium [AUC  0.787 (0.019)], and large 
[AUC  0.903 (0.013)] error sizes; and performed signiﬁ cantly better than LabRe-
spond [z  1.99 (p  0.05), z  2.77 (p  0.01), and z  4.57 (p  0.001), respectively]
and the logistic model [z  1.71 (p  0.05), z  5.28 (p  0.001), and z  8.87 (p 
0.001), respectively]. CONCLUSIONS: A BN model detects errors better and with 
less information than existing automated models, suggesting that Bayesian model can 
be an effective means for reducing medical costs in the laboratory
PGI20
CLINICAL OUTCOMES AND PATTERNS OF CARE IN PATIENTS WITH
CHRONIC LIVER DISEASE, BRIDGING FIBROSIS, AND CIRRHOSIS: 
ADAPTABLE METHODOLOGIES FOR THE DESIGN, IMPLEMENTATION
AND CONDUCT OF MULTI-NATIONAL, RETROSPECTIVE CHART
REVIEW STUDIES
Payne KA1, Lordan N2, Duran B2, Ishak KJ1, Grotzinger K3
1United BioSource Corporation, Montreal, QC, Canada, 2United BioSource Corporation, 
Lexington, MA, USA, 3GlaxoSmithKline, Collegeville, PA, USA
OBJECTIVES: Retrospective chart review data can be important inputs to economic 
models or other burden of illness evaluations. Traditional paper-based approaches and 
local site monitoring can be cost and time prohibitive. A case study of an efﬁ cient,
adaptable design and electronic data capture methodology for the collection of multi-
national clinical, and resource utilization chart data is presented. METHODS: A ret-
rospective chart review study of patients with CLD, bridging ﬁ brosis, and cirrhosis 
from 10 liver centers (7 US; 3 EU) was conducted (eligibility period  6/1/04 to 
5/31/06; study period  minimum of 12 months). Demographics, clinical and health
economic data were collected. All potentially eligible patients were identiﬁ ed by the
sites, but the ﬁ nal random selection of the target cohort and its disposition was con-
trolled centrally through a web-based tool. RESULTS: Data from 864 patient charts 
(62.8% male; mean age 52.3 years) were abstracted over one year. Data abstraction
spanned 22 to 52 weeks depending on the site and its resources. The standardized
eCRF worked well for the capture of multi-national data. Quality was maintained by
electronic validation rules applied at the point of data entry and shown by data com-
pleteness and a minimum of data queries. Database lock was achieved in less than
three weeks following the last data entry. Remote training of data abstractors by
WebEx proved efﬁ cient. Data have been used successfully to inform clinical trial design
and to estimate the cost of illness. Main challenges included timely contracting of sites,
the need for site-speciﬁ c algorithms to identify charts, and analytical methods tailored
to naturalistic data. CONCLUSIONS: A well designed CRF and web-based cohort
control and data capture tool can provide a practical and efﬁ cient means of collecting 
high quality, multi-national outcomes data without the need for costly site visits and 
local monitoring.
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ASSESSMENT OF THE EFFECTIVENESS OF “AFFINEX FLAT STOMACH” 
AFTER 14 DAYS OF TREATMENT
Taieb C
Pierre Fabre, Boulogne, France
OBJECTIVES: Since it houses the digestive system, the least sign of digestive problems
shows up in the stomach. Fermentation, carbonated drinks, air swallowed while 
eating, constipation  .  .  .  but also stress or strong emotions: it becomes painful and
bloated. Evaluate the beneﬁ t of using “afﬁ nex ﬂ at stomach” as part of a weight loss 
regime. METHODS: Prospective pragmatic evaluation under real-life conditions. The
pharmacist gave a double questionnaire along with the product to all adult female
customers who had started (or were about to start) a weight loss regimen and who
asked the pharmacy for help or advice. TOOLS Validated questionnaires were used 
(SF 12 and BISS (Body Index States Scale)). Moreover, waist measurement and symp-
toms were assessed and organized in a single score (Pain, Bloating, Belching, Spasm, 
Transit problems, Flatulence and Nausea). RESULTS: A total of 178 female subjects
included, age: 40.8 o 12.3 years with an average BMI of 23.5 o 3.8 kg/m², the score 
of the symptoms was 146. With regards to QoL scales, the average scores on inclusion 
